S&P 500   3,026.81 (-2.87%)
DOW   26,169.69 (-2.92%)
QQQ   209.19 (-3.37%)
FB   192.16 (-2.56%)
MSFT   163.75 (-3.77%)
GOOGL   1,355.80 (-2.49%)
AMZN   1,914.19 (-3.30%)
CGC   18.13 (-8.53%)
NVDA   253.49 (-5.29%)
BABA   202.67 (-2.91%)
MU   50.28 (-3.99%)
GE   10.45 (-4.57%)
TSLA   679.16 (-12.79%)
AMD   42.22 (-11.10%)
T   35.91 (-3.21%)
ACB   1.36 (-10.56%)
F   6.97 (-3.33%)
NFLX   386.90 (+2.02%)
BAC   29.24 (-4.54%)
DIS   119.54 (-3.10%)
GILD   75.21 (+0.67%)
S&P 500   3,026.81 (-2.87%)
DOW   26,169.69 (-2.92%)
QQQ   209.19 (-3.37%)
FB   192.16 (-2.56%)
MSFT   163.75 (-3.77%)
GOOGL   1,355.80 (-2.49%)
AMZN   1,914.19 (-3.30%)
CGC   18.13 (-8.53%)
NVDA   253.49 (-5.29%)
BABA   202.67 (-2.91%)
MU   50.28 (-3.99%)
GE   10.45 (-4.57%)
TSLA   679.16 (-12.79%)
AMD   42.22 (-11.10%)
T   35.91 (-3.21%)
ACB   1.36 (-10.56%)
F   6.97 (-3.33%)
NFLX   386.90 (+2.02%)
BAC   29.24 (-4.54%)
DIS   119.54 (-3.10%)
GILD   75.21 (+0.67%)
S&P 500   3,026.81 (-2.87%)
DOW   26,169.69 (-2.92%)
QQQ   209.19 (-3.37%)
FB   192.16 (-2.56%)
MSFT   163.75 (-3.77%)
GOOGL   1,355.80 (-2.49%)
AMZN   1,914.19 (-3.30%)
CGC   18.13 (-8.53%)
NVDA   253.49 (-5.29%)
BABA   202.67 (-2.91%)
MU   50.28 (-3.99%)
GE   10.45 (-4.57%)
TSLA   679.16 (-12.79%)
AMD   42.22 (-11.10%)
T   35.91 (-3.21%)
ACB   1.36 (-10.56%)
F   6.97 (-3.33%)
NFLX   386.90 (+2.02%)
BAC   29.24 (-4.54%)
DIS   119.54 (-3.10%)
GILD   75.21 (+0.67%)
S&P 500   3,026.81 (-2.87%)
DOW   26,169.69 (-2.92%)
QQQ   209.19 (-3.37%)
FB   192.16 (-2.56%)
MSFT   163.75 (-3.77%)
GOOGL   1,355.80 (-2.49%)
AMZN   1,914.19 (-3.30%)
CGC   18.13 (-8.53%)
NVDA   253.49 (-5.29%)
BABA   202.67 (-2.91%)
MU   50.28 (-3.99%)
GE   10.45 (-4.57%)
TSLA   679.16 (-12.79%)
AMD   42.22 (-11.10%)
T   35.91 (-3.21%)
ACB   1.36 (-10.56%)
F   6.97 (-3.33%)
NFLX   386.90 (+2.02%)
BAC   29.24 (-4.54%)
DIS   119.54 (-3.10%)
GILD   75.21 (+0.67%)
Log in

NASDAQ:ONVO - Organovo Stock Price, Forecast & News

$0.28
-0.01 (-3.45 %)
(As of 02/27/2020 10:25 AM ET)
Today's Range
$0.26
Now: $0.28
$0.27
50-Day Range
$0.28
MA: $0.37
$0.49
52-Week Range
$0.22
Now: $0.28
$1.16
Volume12,287 shs
Average Volume417,183 shs
Market Capitalization$36.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.09 million
Book Value$0.22 per share

Profitability

Net Income$-26,640,000.00
Net Margins-798.68%

Miscellaneous

Employees70
Market Cap$36.54 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.


Organovo (NASDAQ:ONVO) Frequently Asked Questions

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The medical research company earned $0.67 million during the quarter, compared to analyst estimates of $0.77 million. Organovo had a negative return on equity of 69.36% and a negative net margin of 798.68%. View Organovo's Earnings History.

When is Organovo's next earnings date?

Organovo is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Organovo.

What is the consensus analysts' recommendation for Organovo?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Organovo.

Has Organovo been receiving favorable news coverage?

News headlines about ONVO stock have trended negative on Thursday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organovo earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Organovo.

Are investors shorting Organovo?

Organovo saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 1,160,000 shares, a decrease of 26.6% from the January 30th total of 1,580,000 shares. Based on an average daily trading volume, of 682,900 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the company's stock are sold short. View Organovo's Current Options Chain.

Who are some of Organovo's key competitors?

What other stocks do shareholders of Organovo own?

Who are Organovo's key executives?

Organovo's management team includes the folowing people:
  • Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
  • Mr. Craig Kussman, Chief Financial Officer (Age 60)
  • Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
  • Mr. Paul Gallant, Gen. Mang. (Age 54)
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications

Who are Organovo's major shareholders?

Organovo's stock is owned by many different of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (14.95%), Renaissance Technologies LLC (5.38%), Essex Investment Management Co. LLC (1.01%) and UBS Group AG (0.07%). View Institutional Ownership Trends for Organovo.

Which institutional investors are selling Organovo stock?

ONVO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Organovo.

Which institutional investors are buying Organovo stock?

ONVO stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Renaissance Technologies LLC and ARK Investment Management LLC. View Insider Buying and Selling for Organovo.

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $0.28.

How big of a company is Organovo?

Organovo has a market capitalization of $36.54 million and generates $3.09 million in revenue each year. The medical research company earns $-26,640,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Organovo employs 70 workers across the globe.View Additional Information About Organovo.

What is Organovo's official website?

The official website for Organovo is http://www.organovo.com/.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]


MarketBeat Community Rating for Organovo (NASDAQ ONVO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  367
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel